Ken Griffin Savara Inc Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.96 - $5.07 $314,820 - $403,065	-79,500 Reduced 86.6%	12,300 $52,000
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $334,524 - $488,076	91,400 Added 22850.0%	91,800 $369,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $1,676 - $2,236	400 New	400 $1,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $3,564 - $4,656	1,200 New	1,200 $4,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $11,360 - $20,022	7,100 New	7,100 $13,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.